Ivonescimab Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Ivonescimab comprises 79 peer-reviewed publications across 15 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Triple Negative Breast Neoplasms, Stomach Neoplasms, Nasopharyngeal Carcinoma, and Carcinoma, Non-Small-Cell Lung. Most recent publication: Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer., Radiol Artif Intell, 2026.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.Xiong A, Wang L, Chen J, et al. · Lancet · 2025
- Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Wang J, Zhou C, Yao W, et al. · Lancet Oncol · 2022
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer.Liu Z, Shan D, Han X, et al. · JAMA · 2025
- Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.HARMONi-A Study Investigators, Fang W, Zhao Y, et al. · JAMA · 2024
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer-Reply.Fang W, Li W, Zhang L, et al. · JAMA · 2025
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer.Cheng WC, Wang G, Mei Q, et al. · JAMA · 2025
- Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.Chen Z, Yang F, Jiang Z, et al. · Lancet · 2025
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.Chao J, Fuchs CS, Shitara K, et al. · JAMA Oncol · 2022
Publications by year
2005–2026: 79 publications.
2005
1
2009
1
2010
1
2011
1
2012
4
2014
2
2015
2
2016
2
2017
3
2018
1
2019
2
2020
1
2021
12
2022
10
2023
7
2024
14
2025
12
2026
3
Publications by indication
Triple Negative Breast Neoplasms (39)
- Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
- Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
- Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
- Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
- Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Stomach Neoplasms (10)
- Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
- Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
- Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16-01.
- Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
Nasopharyngeal Carcinoma (8)
- Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
- Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
- Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
- Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Carcinoma, Non-Small-Cell Lung (6)
- The next generation of immunotherapies for lung cancers.
- Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
- Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
- A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
- Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Meningeal Carcinomatosis (6)
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer.
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer-Reply.
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer.
- Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.
- Ivonescimab: First Approval.
Squamous Cell Carcinoma of Head and Neck (2)
- Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Publications by journal
- J Clin Oncol9 papers
- JAMA5 papers
- N Engl J Med4 papers
- J Thorac Oncol4 papers
- Breast Cancer Res Treat4 papers
- JAMA Oncol4 papers
- Lancet3 papers
- Nat Med3 papers
- Clin Cancer Res3 papers
- Radiol Imaging Cancer3 papers
All Ivonescimab publications (79)
2026 (3 papers)
- Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.Teng X, Ma J, Zhang J, et al. · Radiol Artif Intell · 2026 · Derived
- Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.Lang JE, Forero-Torres A, Yee D, et al. · NPJ Breast Cancer · 2026 · Derived
- Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.Hensley M, Lengfeld J, Stoesz S, et al. · Front Oncol · 2026 · Derived
2025 (12 papers)
- The next generation of immunotherapies for lung cancers.Zhao S, Zhao H, Yang W, et al. · Nat Rev Clin Oncol · 2025 · Trial result
- Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.Xiong A, Wang L, Chen J, et al. · Lancet · 2025 · Trial result
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer.Liu Z, Shan D, Han X, et al. · JAMA · 2025 · Trial result
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer-Reply.Fang W, Li W, Zhang L, et al. · JAMA · 2025 · Trial result
- Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer.Cheng WC, Wang G, Mei Q, et al. · JAMA · 2025 · Trial result
- Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.Chen Z, Yang F, Jiang Z, et al. · Lancet · 2025 · Trial result
- Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.Wolf DM, Yau C, Campbell M, et al. · JCO Precis Oncol · 2025 · Derived
- Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.Rugo HS, Campbell M, Yau C, et al. · Breast Cancer Res Treat · 2025 · Derived
- Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.Leon-Ferre RA, Dimitroff K, Yau C, et al. · Breast Cancer Res · 2025 · Derived
- A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images.Jing B, Wang J · Phys Med Biol · 2025 · Derived
- Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.Gilad M, Partridge SC, Iima M, et al. · Radiol Imaging Cancer · 2025 · Derived
- Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial.Chen Z, Wu L, Wang Q, et al. · J Thorac Oncol · 2025 · Background
2024 (14 papers)
- A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.Wang L, Luo Y, Ren S, et al. · J Thorac Oncol · 2024 · Trial result
- Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors.Naito Y, Nakamura S, Kawaguchi-Sakita N, et al. · Int J Clin Oncol · 2024 · Trial result
- Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.Lorenzen S, Götze TO, Thuss-Patience P, et al. · J Clin Oncol · 2024 · Trial result
- Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.HARMONi-A Study Investigators, Fang W, Zhao Y, et al. · JAMA · 2024 · Trial result
- Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.Frentzas S, Austria Mislang AR, Lemech C, et al. · J Immunother Cancer · 2024 · Trial result
- Ivonescimab: First Approval.Dhillon S · Drugs · 2024 · Trial result
- Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.Bardia A, Rugo HS, Tolaney SM, et al. · J Clin Oncol · 2024 · Trial result
- Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial.Zuo WJ, Chen L, Shen Y, et al. · Ther Adv Med Oncol · 2024 · Derived
- Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Shatsky RA, Trivedi MS, Yau C, et al. · Nat Med · 2024 · Derived
- Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.Rediti M, Venet D, Joaquin Garcia A, et al. · Nat Commun · 2024 · Derived
- Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.Northrop A, Christofferson A, Umashankar S, et al. · J Am Med Inform Assoc · 2024 · Derived
- Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.Li W, Partridge SC, Newitt DC, et al. · Radiol Imaging Cancer · 2024 · Derived
- Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Khoury K, Meisel JL, Yau C, et al. · Nat Med · 2024 · Derived
- RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.Spigel DR, Dowlati A, Chen Y, et al. · J Clin Oncol · 2024 · Background
2023 (7 papers)
- AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.Zhao Y, Chen G, Chen J, et al. · EClinicalMedicine · 2023 · Trial result
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. · J Clin Oncol · 2023 · Trial result
- Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.André T, Tougeron D, Piessen G, et al. · J Clin Oncol · 2023 · Trial result
- Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.Parker BA, Shatsky RA, Schwab RB, et al. · Breast Cancer Res Treat · 2023 · Derived
- Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.Onishi N, Bareng TJ, Gibbs J, et al. · Radiol Imaging Cancer · 2023 · Derived
- Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.Mukhtar RA, Chau H, Woriax H, et al. · Ann Surg · 2023 · Derived
- Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.Gallagher RI, Wulfkuhle J, Wolf DM, et al. · Cell Rep Med · 2023 · Derived
2022 (10 papers)
- Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Wang J, Zhou C, Yao W, et al. · Lancet Oncol · 2022 · Trial result
- Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16-01.Tran-Minh ML, Lehmann-Che J, Lambert J, et al. · Clin Res Hepatol Gastroenterol · 2022 · Trial result
- Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.Nie RC, Chen GM, Yuan SQ, et al. · Ann Surg Oncol · 2022 · Trial result
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.Chao J, Fuchs CS, Shitara K, et al. · JAMA Oncol · 2022 · Trial result
- Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Wolf DM, Yau C, Wulfkuhle J, et al. · Cancer Cell · 2022 · Derived
- Postneoadjuvant treatment for triple-negative breast cancer.Trapani D, Ferraro E, Giugliano F, et al. · Curr Opin Oncol · 2022 · Derived
- Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.Symmans WF, Yau C, Chen YY, et al. · JAMA Oncol · 2022 · Derived
- Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.Osdoit M, Yau C, Symmans WF, et al. · JAMA Surg · 2022 · Derived
- Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.Wise-Draper TM, Gulati S, Palackdharry S, et al. · Clin Cancer Res · 2022 · Background
- Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer.Li L, Liu T, Liu Q, et al. · Front Pharmacol · 2022 · Background
2021 (12 papers)
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.Sung H, Ferlay J, Siegel RL, et al. · CA Cancer J Clin · 2021 · Trial result
- Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.Mai HQ, Chen QY, Chen D, et al. · Nat Med · 2021 · Trial result
- Global burden of oesophageal and gastric cancer by histology and subsite in 2018.Arnold M, Ferlay J, van Berge Henegouwen MI, et al. · Gut · 2021 · Trial result
- Atezolizumab in the treatment of metastatic triple-negative breast cancer.Pérez-García J, Soberino J, Racca F, et al. · Expert Opin Biol Ther · 2021 · Derived
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.Nanda R, Liu MC, Yau C, et al. · JAMA Oncol · 2021 · Derived
- Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.I-SPY2 Trial Consortium, Yee D, DeMichele AM, et al. · JAMA Oncol · 2021 · Derived
- RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.Engebraaten O, Yau C, Berg K, et al. · Nat Commun · 2021 · Derived
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.Chien AJ, Tripathy D, Albain KS, et al. · J Clin Oncol · 2021 · Derived
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.Uppaluri R, Campbell KM, Egloff AM, et al. · Clin Cancer Res · 2021 · Background
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.Socinski MA, Nishio M, Jotte RM, et al. · J Thorac Oncol · 2021 · Background
- Cancer Statistics, 2021.Siegel RL, Miller KD, Fuchs HE, et al. · CA Cancer J Clin · 2021 · Background
- Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial.Shi M, Gu A, Tu H, et al. · Ann Oncol · 2021 · Background
2020 (1 paper)
- Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.Pietrantonio F, Miceli R, Raimondi A, et al. · J Clin Oncol · 2020 · Trial result
2019 (2 papers)
- Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.Zhang Y, Chen L, Hu GQ, et al. · N Engl J Med · 2019 · Trial result
- Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.Shi M, Sun J, Zhou J, et al. · Invest New Drugs · 2019 · Background
2018 (1 paper)
- The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.Severson TM, Wolf DM, Yau C, et al. · Breast Cancer Res · 2018 · Derived
2017 (3 papers)
- Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.Sun Y, Li WF, Chen NY, et al. · Lancet Oncol · 2017 · Trial result
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.Hsu C, Lee SH, Ejadi S, et al. · J Clin Oncol · 2017 · Trial result
- Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Antonia SJ, Villegas A, Daniel D, et al. · N Engl J Med · 2017 · Background
2016 (2 papers)
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.Rugo HS, Olopade OI, DeMichele A, et al. · N Engl J Med · 2016 · Derived
- Adaptive Randomization of Neratinib in Early Breast Cancer.Park JW, Liu MC, Yee D, et al. · N Engl J Med · 2016 · Derived
2015 (2 papers)
- VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.Voron T, Colussi O, Marcheteau E, et al. · J Exp Med · 2015 · Trial result
- Nasopharyngeal carcinoma: a review.Petersson F · Semin Diagn Pathol · 2015 · Background
2014 (2 papers)
- Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis.Choi YY, Bae JM, An JY, et al. · J Surg Oncol · 2014 · Trial result
- PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.Chen BJ, Chapuy B, Ouyang J, et al. · Clin Cancer Res · 2014 · Trial result
2012 (4 papers)
- Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).Lin C, Buxton MB, Moore D, et al. · Breast Cancer Res Treat · 2012 · Trial result
- Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.Hylton NM, Blume JD, Bernreuter WK, et al. · Radiology · 2012 · Trial result
- Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.Esserman LJ, Berry DA, DeMichele A, et al. · J Clin Oncol · 2012 · Trial result
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).Esserman LJ, Berry DA, Cheang MC, et al. · Breast Cancer Res Treat · 2012 · Trial result
2011 (1 paper)
- Accelerating identification and regulatory approval of investigational cancer drugs.Esserman LJ, Woodcock J · JAMA · 2011 · Background
2010 (1 paper)
- Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure.Boyd JA, Hubbs JL, Kim DW, et al. · J Thorac Oncol · 2010 · Background
2009 (1 paper)
- I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.Barker AD, Sigman CC, Kelloff GJ, et al. · Clin Pharmacol Ther · 2009 · Background
2005 (1 paper)
- Nasopharyngeal carcinoma.Wei WI, Sham JS · Lancet · 2005 · Background
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Thu, 14 May 2026 21:48:17 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).